Completed PHASE3 INTERVENTIONAL 2-arm NCT00734071

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder

Sponsor: H. Lundbeck A/S

Conditions Generalized Anxiety Disorder

Interventions Placebo Vortioxetine

Updated 7 times since 2017 Last updated: Oct 25, 2013 Started: Jun 30, 2008 Primary completion: Jan 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Generalized Anxiety Disorder, this trial is completed. The trial is conducted by H. Lundbeck A/S and has accumulated 7 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S
Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Arcadia, United States , Austin, United States , Baltimore, United States , Bradenton, United States , Brooklyn, United States , Charleston, United States , Cincinnati, United States , Coral Gables, United States , Fall River, United States and 23 more locations